FDA Seeks To Speed Seizure, Injunction Decisions With More Collaboration
This article was originally published in The Gray Sheet
Executive Summary
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.
You may also be interested in...
People In Brief
New CDRH compliance director: Steve Silverman is the new director of the FDA device center's Office of Compliance, agency staffers informed "The Gray Sheet" Sept. 10. Silverman, who has been a senior advisor in the compliance office for the past year, takes the helm from long-time Compliance Director Tim Ulatowski, who will retire from the agency Jan. 1, 2011 (1"The Gray Sheet" May 3, 2010). For the remainder of the year, Ulatowski will advise Silverman and lead special projects in the office. Prior to joining CDRH, Silverman was assistant director of the drug center's Office of Compliance. He has also worked in FDA's Office of Chief Counsel
FDA's New Enforcement Approach Will Put More Warning Letters In The Mail
FDA Commissioner Margaret Hamburg is honing the agency's enforcement system to get warning letters out faster and create a formal "close-out" process that publicly indicates when a firm has addressed FDA's concerns
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.